Folate and coronary heart disease

Current Opinion in Lipidology

Volumn 9, Issue 1, 1998, Pages 17-22

  Verhoef, Petra ^a   Stampfer, Meir J ^b,c   Rimm, Eric B ^b,c  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE;

AMINO ACID METABOLISM; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET; FEMALE; FOLIC ACID BLOOD LEVEL; GENETIC POLYMORPHISM; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW;

5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CORONARY DISEASE; FOLIC ACID; HOMOCYSTEINE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NUTRITION POLICY; OXIDOREDUCTASES; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0031962779     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199802000-00005     Document Type: Review

References (41)

1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274:1049-1057.
2. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF. Belanger AJ, et al. Relationship between plasma homocysteine, vitamin status and extracranial carotid-artery stenosis in the Framingham Study Population. J Nutr 1996; 126:1258S-1265S.
3. Tucker KL, Mahnken B, Wilson PWF, Jacques P, Selhub J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA 1996; 276:1879-1885.
4. Brattström L. Vitamins as homocysteine-lowering agents. J Nutr 1996: 126:1276S-1280S.
5. Stampfer MJ, Rimm EB. Folate and cardiovascular disease: why we need a trial now. JAMA 1996; 275:1929-1930.
6. Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Rodney CPG, Alvarez JO, et al. Plasma homocyst (e)ine, folate, and vitamin B-12 concentrations and risk for early onset coronary artery disease. Am J Clin Nutr 1994; 59:940-948.
7. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, et al. Homocysteine metabolism and risk of myocardial infarction: relationship with vitamins B6, B12 and folate. Am J Epidemiol 1996; 143:845-859.
8. Shane B. Folate chemistry and metabolism. In: Folate in health and disease. L.B. Bailey (editor). New York: Marcel Dekker Inc., 1995. pp. 1-21.
9. Gregory III JF. The bioavailability of folate. In: Folate in health and disease. L.B. Bailey (editor). New York: Marcel Dekker Inc., 1995. pp. 195-236.
10. Food and Nutrition Board. Recommended dietary allowances. 10th rev edn. Washington, DC: National Academy of Sciences; 1989.
11. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-137.
12. Czeizel AE, Dudds I. Prevention of first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832-1835.
13. De Bree A, Van Dusseldorp M, Brouwer IA, Van het Hof KH, Steegers-Theunissen RPM. Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 1997; 51:643-660.
14. Verhoef P, Stampfer MJ. Homocysteine - a risk factor for coronary artery disease In: Heart disease - a textbook of cardiovascular medicine (suppl 2). E. Braunwald (editor). WB Saunders Company, Orlando, Florida, USA, 1997.
15. Kang SS, Passen EL, Ruggie N, Wong PW, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993; 88:1463-1469.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthew's RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
17. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RMJ (ed): "Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function". New York: Marcel Dekker Inc., 1992, 183-236.
18. Wouters MGAJ, Moorrees MThEC, Van der Mooren MJ, Blom HJ, Boers GHJ, Schellekens LA, Thomas CMG, Eskes TKAB. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995; 25:801-805.
19. Andersson A, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hultherg B: Plasma homocysteine before and after methionine loading with regard to age, gender and menopausal status. Eur J Clin Invest 1992; 22:74-87.
20. Nygard O, Vollset SE, Refsum H, Stensvoid I, Iverdal A, Nordrehaug JE, et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA 1995; 274:1526-1533.
21. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential association to arteriosclerotic outcomes. Kidney Int 1997; 52:10-20.
22. Subar AF, Block G, James LD. Folate intake and food sources in the US population. Am J Clin Nutr 1989; 50:508-516.
23. Graham IH, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997; 277:1775-1781. In a European case control study of 750 cases of atherosclerotic vascular disease and BDO controls, a dose response effect was noted between homocysteine and risk, for both sexes. Both fasting and post-methionine homocysteine concentrations were related to increased risk.
24. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The atherosclerosis risk in communities study. Circulation 1993; 87:1107-1113.
25. Den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759-762.
26. Verhoef P, Stampfer MJ. Prospective studies of homocysteine and cardiovascular disease. Nutr Rev 1995; 53:283-288.
27. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230-236. This prospective study with a median follow-up of 4 6 years among 587 patients with angiographically confirmed coronary artery disease showed a strong, graded relation of plasma total homocysteine levels with overall mortality (n = 64) and death due to cardiovascular disease (n = 50).
28. Verhoef P, Kok FJ, Kruyssen HACM, Schouten EG, Witteman JCM, Grobbee DE, Ueland PM, Refsum H. Plasma total homocysteine, B-vitamins and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:989-995.
29. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24:704-709.
30. Robinson K, Mayer EL, Miller DP, Green R, Van Lonte F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92:2825-2830.
31. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996; 94:2154-2158.
32. Kluijrmans LAJ, Van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, Van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58:35-41.
33. Ma J, Stampfer MJ, Hennekens CH, Frost P, Selhub J, Hossford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94:2410-2416. In a comparison of 293 Physicians' Health Study participants who developed myocardial infarction during 8 years of follow-up and 290 control subjects, the homozygous genotype for the C677T polymorphism in methylenetetrahydrofolate reductase was associated with significantly increased homocysteine levels but not with increased myocardial infarction.
34. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996; 275:1893-1896 In a cohort study among 5056 Canadian men and women, 165 CHD deaths occurred during 15 years follow-up. There was an inverse association between serum folate levels and risk of CHD.
35. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow R, Terry P, Tishler PV, et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996; 15:136-143.
36. Rimm EB, Willett WC, Manson J, Speizer F, Hennekens C, Stampfer MJ. Folate and vitamin B6 intake and risk of myocardial infarction among US women [abstract]. Am J Epidemiol 1996; 143:536.
37. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Willett WC. Dietary Folate, vitamin B6, and vitamin B12 intake and risk of CHD among a large population of US men [abstract]. Circulation 1996; 93:625.
38. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94:2743-2748.
39. Tucker KL, Selhub J, Wilson PWF, Rosenberg IH. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. J Nutr 1996; 126:3025-3031.
40. Bendich A. Folic acid and prevention of neural tube birth defects: critical asssessment of FDA proposals to increase folic acid intakes. J Nutr Educ 1994; 26:294-299.
41. Appel LJ. Folic acid fortification of food [letter]. J Am Med Assoc 1996; 275:681-682.